Skip to main
LBRX

LBRX Stock Forecast & Price Target

LBRX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LB Pharmaceuticals is positioned for long-term success with its promising drug candidate, LB-102, which targets a large and growing market of neuropsychiatric diseases. The company's strategic partnership with the FDA allows for a streamlined development and registration process, and its "Buy" rating from analysts highlights the potential of the drug in the market. Additionally, LB Pharmaceuticals' successful products in treating mood disorders generate significant annual revenue and may provide a stable foundation for the company's future growth and success.

Bears say

LB Pharmaceuticals is facing several key risks that contribute to a negative outlook. These include the potential for failure to enroll the pivotal NOVA-2 trial in a timely manner, negative top-line data from the trial, and delays or setbacks in additional clinical trials of LB-102. Additionally, competition from established drugs and emerging agents in the neuropsychiatry space, regulatory uncertainties, and the need for additional capital to fund late-stage development pose significant risks to the company's success. Furthermore, the political landscape in the U.S. may lead to changes in drug pricing and reimbursement policies, potentially impacting LB Pharmaceuticals' financials.

LBRX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LB Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LB Pharmaceuticals Inc (LBRX) Forecast

Analysts have given LBRX a Strong Buy based on their latest research and market trends.

According to 5 analysts, LBRX has a Strong Buy consensus rating as of Jun 2, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $46.60, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $46.60, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LB Pharmaceuticals Inc (LBRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.